RxDoctor Payments Data

Luis Rodriguez Gonzalez, MD

General Practice · Tampa, FLNPI 1770504565

Payments from drug & device makers

$462in general payments, 2019–2025

Across 23 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$97
  • Lilly USA, LLC$77
  • Bayer$65
  • Dexcom, Inc.$64
  • Novo Nordisk$45
  • Novartis$23
  • plus $91 from 5 others

What the payments were for

  • Food & beverage$462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott4$97
Lilly USA, LLC4$77
Bayer3$65
Dexcom, Inc.3$64
Novo Nordisk3$45
Novartis1$23
Gilead1$22
Exact Sciences1$21
Amgen1$18
GSK1$15
MVP Orthopedics Inc1$14

How this compares

$462 in reported general payments places this provider in the 60th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$10,721
Medicare patients
38
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$203,788
TrulicityDulaglutide49$81,454
MounjaroTirzepatide44$69,987
FarxigaDapagliflozin Propanediol34$43,596
JardianceEmpagliflozin35$38,371
EliquisApixaban21$26,474
Combivent RespimatIpratropium/Albuterol Sulfate20$16,100
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,783
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen174$3,797
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen125$3,786
Atorvastatin Calcium406$3,169
Albuterol Sulfate HfaAlbuterol Sulfate76$2,922
Diclofenac Sodium287$2,871
Methylprednisolone125$2,789
Oxycodone Hcl124$2,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$203,788122 claims
Lilly USA, LLCTrulicity, Mounjaro$77$151,44293 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,901 general practice providers in Florida.

Other general practice in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →